Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system comprises an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone858-888-7600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$12 million
Profitability
Miscellaneous
Employees77
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
BioNano Genomics (NASDAQ:BNGO) Frequently Asked Questions
What is BioNano Genomics' stock symbol?
BioNano Genomics trades on the NASDAQ under the ticker symbol "BNGO."
How were BioNano Genomics' earnings last quarter?
BioNano Genomics Inc (NASDAQ:BNGO) issued its earnings results on Thursday, August, 8th. The company reported ($0.71) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.14. The firm earned $2.18 million during the quarter, compared to analyst estimates of $2.56 million. BioNano Genomics had a negative net margin of 247.03% and a negative return on equity of 347.02%. View BioNano Genomics' Earnings History.
When is BioNano Genomics' next earnings date?
What guidance has BioNano Genomics issued on next quarter's earnings?
BioNano Genomics issued an update on its third quarter 2019 earnings guidance on Thursday, October, 17th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.3-3.3 million, compared to the consensus revenue estimate of $4.44 million.
What price target have analysts set for BNGO?
2 analysts have issued twelve-month target prices for BioNano Genomics' shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate BioNano Genomics' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 320.1% from the stock's current price. View Analyst Price Targets for BioNano Genomics.
What is the consensus analysts' recommendation for BioNano Genomics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNano Genomics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioNano Genomics.
What are Wall Street analysts saying about BioNano Genomics stock?
Here are some recent quotes from research analysts about BioNano Genomics stock:
- 1. According to Zacks Investment Research, "BioNano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents. BioNano Genomics, Inc. is based in San Diego, United States. " (9/23/2019)
- 2. Maxim Group analysts commented, "Bionano reported 2Q19 with revenues of $2.2M and a net loss of ($7.7M). The company ended the period with $15.3M in cash on the balance sheet." (8/9/2019)
Has BioNano Genomics been receiving favorable news coverage?
Media stories about BNGO stock have trended somewhat negative this week, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. BioNano Genomics earned a news sentiment score of -1.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for BioNano Genomics.
Are investors shorting BioNano Genomics?
BioNano Genomics saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 167,700 shares, an increase of 310.0% from the August 30th total of 40,900 shares. Based on an average daily volume of 93,000 shares, the days-to-cover ratio is currently 1.8 days. Approximately 3.4% of the shares of the company are short sold. View BioNano Genomics' Current Options Chain.
Who are some of BioNano Genomics' key competitors?
Some companies that are related to BioNano Genomics include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), PerkinElmer (PKI), Avantor (AVTR), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX) and Fluidigm (FLDM).
What other stocks do shareholders of BioNano Genomics own?
Who are BioNano Genomics' key executives?
BioNano Genomics' management team includes the folowing people:
- Dr. Robert Erik Holmlin, Pres, CEO & Director (Age 51)
- Mr. Michael J. Ward, Chief Financial Officer (Age 47)
- Mr. Warren Robinson, Chief Commercial Officer (Age 50)
- Mr. Mark Borodkin, Chief Operating Officer (Age 45)
- Heather Adams, Sec.
When did BioNano Genomics IPO?
(BNGO) raised $16 million in an initial public offering (IPO) on the week of August 20th 2018. The company issued 2,500,000 shares at $6.00-$7.00 per share. Roth Capital Partners and Maxim Group acted as the underwriters for the IPO and LifeSci Capital was co-manager.
How do I buy shares of BioNano Genomics?
Shares of BNGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is BioNano Genomics' stock price today?
One share of BNGO stock can currently be purchased for approximately $1.67.
How big of a company is BioNano Genomics?
BioNano Genomics has a market capitalization of $18.16 million and generates $12 million in revenue each year. The company earns $-18,500,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. BioNano Genomics employs 77 workers across the globe.View Additional Information About BioNano Genomics.
What is BioNano Genomics' official website?
How can I contact BioNano Genomics?
BioNano Genomics' mailing address is 9540 TOWNE CENTRE DRIVE SUITE 100, SAN DIEGO CA, 92121. The company can be reached via phone at 858-888-7600 or via email at [email protected]
MarketBeat Community Rating for BioNano Genomics (NASDAQ BNGO)
MarketBeat's community ratings are surveys of what our community members think about BioNano Genomics and other stocks. Vote "Outperform" if you believe BNGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BNGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
